NEW YORK–(BUSINESS WIRE)–Even Realities, the company behind camera-free, display-first smart glasses, today introduced Brown 2, a new tortoiseshell-inspired colorway for Even G2, alongside two accessories: Even G2 Clip (Polarized) and the Even G2 Cha…
Author: Business Wire
Allotex Five-Year Clinical Results on Its TransForm Human Tissue Platform
BOSTON–(BUSINESS WIRE)–Allotex today announced five-year clinical observations presented in an ESCRS Free Paper by Cafer Tanrıverdi, MD, and collaborators from Medipol University and other clinical institutions in Istanbul. The study evaluated steril…
STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results a…
NextGen Healthcare Introduces N.I.A.™ for Insights, an Analytics Agent That Helps Healthcare Organizations Make Decisions Faster
SAN DIEGO–(BUSINESS WIRE)– #NextGenHealthcare–NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, today announced N.I.A.™ (NextGen Intelligent Agent) for Insights, an analytics agent built directly into…
NextGen Healthcare Introduces N.I.A.™ for Insights, an Analytics Agent That Helps Healthcare Organizations Make Decisions Faster
SAN DIEGO–(BUSINESS WIRE)– #NextGenHealthcare–NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, today announced N.I.A.™ (NextGen Intelligent Agent) for Insights, an analytics agent built directly into…
NextGen Healthcare Introduces N.I.A.™ for Insights, an Analytics Agent That Helps Healthcare Organizations Make Decisions Faster
SAN DIEGO–(BUSINESS WIRE)– #NextGenHealthcare–NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, today announced N.I.A.™ (NextGen Intelligent Agent) for Insights, an analytics agent built directly into…
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
GENEVA–(BUSINESS WIRE)–Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
GENEVA–(BUSINESS WIRE)–Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2
Perfect Corp. Launches GenAI-Powered Glasses Removal, Letting Glasses Wearers Try On New Frames Without Taking Theirs Off
NEW YORK–(BUSINESS WIRE)–Perfect Corp. (NYSE: PERF), the leading AI and AR beauty and fashion tech provider, today announced a generative AI upgrade to its AI Glasses Virtual Try-On solution, led by the new Glasses Removal feature. Built on generativ…
FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
GENEVA–(BUSINESS WIRE)–FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
GENEVA–(BUSINESS WIRE)–FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment …
Warby Parker to Announce Third Quarter 2026 Financial Results on November 5, 2026
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2026, will be released befor…
National Vision Launches 2026-2027 Scholarship Program, Exploring the Balance Between Innovation and Human Connection
ALPHARETTA, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE), one of the largest optical retail companies in the United States, announced today that its annual scholarship program is open for entries, offering eligible optometry stude…
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced two presentations of data for STK-002 at t…
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Tho…
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, …
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compare…
Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium
ANN ARBOR, Mich.–(BUSINESS WIRE)–Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, sa…
Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium
ANN ARBOR, Mich.–(BUSINESS WIRE)–Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, sa…